Market closedADR
Trinity Biotech plc ADS/$TRIB
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Trinity Biotech plc ADS
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Ticker
$TRIB
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Bray, Ireland
Employees
380
Website
TRIB Metrics
BasicAdvanced
$12M
-
-$2.29
1.13
-
Price and volume
Market cap
$12M
Beta
1.13
52-week high
$0.86
52-week low
$0.48
Average daily volume
41K
Financial strength
Current ratio
1.643
Quick ratio
0.865
Long term debt to equity
-346.792
Total debt to equity
-355.763
Interest coverage (TTM)
-1.39%
Management effectiveness
Return on assets (TTM)
-8.19%
Return on equity (TTM)
92.77%
Valuation
Price to revenue (TTM)
0.099
Price to book
-0.25
Price to tangible book (TTM)
-0.09
Price to free cash flow (TTM)
-0.375
Growth
Revenue change (TTM)
-17.18%
Earnings per share change (TTM)
-38.72%
3-year revenue growth (CAGR)
-17.74%
3-year earnings per share growth (CAGR)
6.71%
TRIB News
AllArticlesVideos
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
GlobeNewsWire·1 month ago
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
GlobeNewsWire·1 month ago
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Trinity Biotech plc ADS stock?
Trinity Biotech plc ADS (TRIB) has a market cap of $12M as of April 25, 2025.
What is the P/E ratio for Trinity Biotech plc ADS stock?
The price to earnings (P/E) ratio for Trinity Biotech plc ADS (TRIB) stock is 0 as of April 25, 2025.
Does Trinity Biotech plc ADS stock pay dividends?
No, Trinity Biotech plc ADS (TRIB) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Trinity Biotech plc ADS dividend payment date?
Trinity Biotech plc ADS (TRIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Trinity Biotech plc ADS?
Trinity Biotech plc ADS (TRIB) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.